Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in Germany - insights from the reload study

被引：0
|
作者：
Bonnemeier, H. [1 ]
Mundhenke, M. [2 ]
Von Mach, T. [2 ]
Huelsebeck, M. [2 ]
机构：
[1] Univ Med Ctr Schleswig Holstein, Dept Electrophysiol & Rhythmol, Kiel, Germany
[2] Bayer Vital GmbH, Leverkusen, Germany
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P3581
引用
收藏
页码：765 / 765
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH REAL-WORLD TREATMENT FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN CHINA
    Yang, L.
    Wu, J.
    VALUE IN HEALTH, 2018, 21 : S63 - S63
  • [2] RIVAROXABAN IN PREVENTION OF STROKE IN ELDERLY PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Yavelov, I. S.
    KARDIOLOGIYA, 2019, 59 (12) : 4 - 11
  • [3] Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation
    Potpara, Tatjana S.
    THROMBOSIS AND HAEMOSTASIS, 2015, 114 (06) : 1093 - 1098
  • [4] Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKETAF and XANTUS
    Camm, A. John
    Amarenco, Pierre
    Haas, Sylvia
    Hess, Susanne
    Kirchhof, Paulus
    Lambelet, Marc
    Bach, Miriam
    Turpie, Alexander G. G.
    EUROPACE, 2019, 21 (03): : 421 - 427
  • [5] Real - world evidence of stroke prevention in patients with non-valvular atrial fibrillation
    Coleman, C.
    Antz, M.
    EUROPEAN HEART JOURNAL, 2016, 37 : 502 - 502
  • [6] COST-EFFECTIVENESS OF RIVAROXABAN IN THE PREVENTION OF STROKE IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN ITALY
    Capri, S.
    Veneziano, M.
    Ricciardi, W. G.
    D'Ausilio, A.
    Pedone, M. P.
    Bianchi, C.
    VALUE IN HEALTH, 2013, 16 (07) : A525 - A526
  • [7] A REAL-WORLD ASSESSMENT OF RISK FOR SEVERE STROKE AND POST-STROKE MORTALITY IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH RIVAROXABAN AND WARFARIN
    Alberts, Mark
    Chen, Yen-Wen
    Lin, Jennifer
    Ding, Zhijie
    Bisht, Deepti
    Kogan, Emily
    Twyman, Kathryn
    Milentijevic, Dejan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1862 - 1862
  • [8] Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer
    Laube, Eva Simona
    Yu, Anthony
    Gupta, Dipti
    Miao, Yimei
    Samedy, Patrick
    Wills, Jonathan
    Harnicar, Stephen J.
    Soff, Gerald A.
    Mantha, Simon
    BLOOD, 2016, 128 (22)
  • [9] Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure
    Martinez, Brandon K.
    Bunz, Thomas J.
    Eriksson, Daniel
    Meinecke, Anna-Katharina
    Sood, Nitesh A.
    Coleman, Craig I.
    ESC HEART FAILURE, 2019, 6 (01): : 10 - 15
  • [10] A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia
    Alosaimi, Hind M.
    Alqahtani, Saeed
    Balkhi, Bander
    Alqahtani, Mishari
    Alzamil, Faisal
    Alhossan, Abdulaziz
    Alqahtany, Fatmah S.
    Alharbi, Abdullah A.
    Alqahtani, Nawaf Abdullah
    Albackr, Hanan
    Elgohary, Ghada
    Algahtani, Farjah H.
    PEERJ, 2022, 10
12345